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BACKGROUND. American Indians and Alaska Natives (AI/AN) experience higher
morbidity and mortality from primary liver cancer than other United States (US)
populations, but racial misclassification in medical records results in underesti-
mates of disease burden.
METHODS. To reduce misclassification, National Program of Cancer Registries and Sur-
veillance, Epidemiology, and End Results data were linked with Indian Health Service
(IHS) enrollment records to compare primary liver cancer incidence and stage at dia-
gnosis between AI/AN and non-Hispanic whites (NHW) living within the regionalized
IHS Contract Health Service Delivery Area counties. Incidence rates are expressed per
100,000 persons and age-adjusted by 19 age groups to the 2000 US standard population.
RESULTS. Overall, AI/AN have a higher proportion of hepatocellular carcinoma com-
pared with NHW, 77.8% versus 66.7%. Liver cancer incidence rates among AI/ANmales
and females were higher than those among NHW males and females for all regions
except for the East. Among males, rates ranged from 7.3 (95% confidence interval [CI],
3.8-12.6) in the East to 17.2 (95% CI, 10.4-26.3) in Alaska. Among females, rates ranged
from 3.8 (95% CI, 1.4-8.2) in the East to 6.9 (95% CI, 3.6-11.6) in Alaska. The AI/AN rates
for all regions were consistently higher than the NHW rates at every age. An increasing
trend among AI/ANwas suggested but did not achieve statistical significance.
CONCLUSIONS. Reducing racial misclassification revealed higher disparities in pri-
mary liver cancer incidence between NHW and AI/AN populations than pre-
viously reported. Further description of the reasons for regional differences in
this disparity is needed, as are programs to reduce risk factors and to diagnose
primary liver cancer at earlier, more treatable stages. Cancer 2008;113(5
supp):1244–55. Published 2008 by the American Cancer Society.*
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T he liver is a common site of metastasis fortumors originating in other organs. In this paper
we will focus on cancers that originate in the liver,
not on cancers that begin at other sites and metasta-
size to the liver. Primary liver cancer refers to a het-
erogeneous group of malignancies that includes
hepatocellular carcinomas (HCC), intrahepatic cho-
langiocarcinomas and, more rarely, angiosarcomas,
hemangiosarcomas, and hepatoblastomas. Risk fac-
tors for liver cancer vary by histology; those asso-
ciated with HCC include chronic infection with
hepatitis B or C viruses, alcoholic cirrhosis, hemo-
chromatosis, nonalcoholic steatohepatitis (NASH),
and primary biliary cirrhosis.1 Alcohol consumption
and possibly tobacco use and diabetes may synergis-
tically increase this risk.2-8 Primary sclerosing cho-
langitis and congenital biliary abnormalities are
strong risk factors for cholangiocarcinoma in the
United States, whereas parasitic biliary infections
and recurrent pyogenic cholangitis play a larger role
worldwide.9-14
American Indians and Alaska Natives (AI/AN) ex-
perience higher morbidity and mortality from pri-
mary liver cancer than other United States (US)
populations.15-18 During the years 2000 to 2004, pri-
mary liver cancer was the 9th leading cause of can-
cer mortality in US males and the 11th in US
females.2 It was, however, 4th among AI/AN males
and 6th among AI/AN females living in counties
served by the Indian Health Service (IHS).16 In addi-
tion, liver cancer mortality rates were 102% higher
for AI/AN males and 150% higher for AI/AN females
than for all races of males and females during this
period. However, AI/AN populations vary greatly in
terms of culture, diet, genetics, and known cancer
risk factors, and thus important regional differences
in cancer incidence may be missed by national sum-
mary statistics. For example, from 1990 to 2001, mor-
tality rates from liver cancer among IHS’s geographic
regions ranged from 5.5 per 100,000 for AI/AN living
on the Pacific Coast to 10.6 in the Southwest, all of
which were higher than the US all-races rate of 4.6.17
Regional differences in the incidence of primary
liver cancer, however, have not been thoroughly
investigated.
Accurate determination of cancer burden is a
critical first step toward addressing health disparities.
High rates of racial misclassification in medical
records and on death certificates make determining
cancer incidence and mortality rates for AI/AN
populations difficult.19,20 Data from the National
Longitudinal Mortality Survey correlating self-identi-
fied race from current population surveys with race
on death certificates found that AI/AN are classified
as another race 44.8% of the time.21 Although wide
regional and urban/rural variation exists, AI/AN are
more likely to be misclassified as another race than
are other racial groups, resulting in underestimates
of both cancer incidence and mortality.22-25
This study links cancer incidence data from cen-
tral cancer registries with IHS patient registration
databases as 1 way to minimize the effects of racial
misclassification.26 Our objective was to compare re-
gional liver cancer incidence rates and stage at diag-
nosis among AI/AN to those in non-Hispanic whites
(NHW) living in the same regions of the United
States. Because urban AI/AN are much less likely to
access IHS services (and therefore less likely to have
racial misclassification corrected through IHS link-
age), we focused on those AI/AN living in IHS Con-
tract Health Service Delivery Areas (CHSDA), defined
as counties containing or abutting federally recog-
nized AI/AN reservations and tribal lands, for whom
the IHS is responsible for medical services.27
MATERIALS AND METHODS
Cancer Cases
We used data from state and regional population-
based cancer registries in the US that collect infor-
mation on newly diagnosed primary cancers. These
registries participate in the National Program of
Cancer Registries (NPCR) of the Centers for Disease
Control and Prevention (CDC), Surveillance, Epide-
miology, and End Results (SEER) program of the
National Cancer Institute (NCI), or both.28-30 Primary
cancer site and histology data were coded according
to the International Classification of Diseases for On-
cology (ICD-O) edition in use at the time of diagno-
sis and are converted to the Third Edition.31
For this study, incidence data for cancer of the
liver and intrahepatic bile ducts refer to invasive
primary cancers (ICD-O-3 site codes C22.0-C22.1);
lymphomas originating in the lymphatic tissue of the
liver and Kaposi sarcomas are excluded. Incident
cancer cases diagnosed during the time period 1999
to 2004 from population-based state cancer registries
that provided permission and that met the United
States Cancer Statistics standard for high-quality data
were included in this analysis (see footnote to Table
1 for list of registries).26 Analysis was restricted to
microscopically confirmed cases for histology only.
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Cancer cases diagnosed during 2001 to 2003 were
staged by use of the 2000 SEER summary staging sys-
tem.32 Collaborative stage data, first reported for
2004, were not available for analysis. Because of the
small number of AI/AN cases, the analyses will
include all primary liver cancers, rather than being
restricted to hepatocellular carcinoma.
To reduce the misclassification of AI/AN cases as
non-Native, all case records from the NPCR and
SEER population-based registries were linked with
the IHS patient registration database. Files were pre-
pared by the registries and sent to the IHS Division
of Epidemiology and Disease Prevention in Albu-
querque, New Mexico for linkage. The IHS provides
medical services to AI/AN persons who are eligible
members of federally recognized tribes. Linkages
applied to key patient identifiers were conducted by
use of LinkPlus,33 a probabilistic linkage software
program developed by CDC.26
The proportion of AI/AN in the total population
is higher in CHSDA counties than in non-CHSDA
counties, and data indicate that there is less racial
misclassification for AI/AN in these counties than in
non-CHDSA counties.34 AI/AN in these counties are
also more likely to access IHS services and therefore
to have any racial misclassification corrected by our
linkage strategy. Analyses were restricted to persons
who reside in CHSDA counties unless otherwise
noted (Table 1). About 56% of the US AI/AN popula-
tion reside in CHSDA counties. This proportion var-
ies by IHS region: Alaska 5 100%; East 5 13.1%;
Northern Plains 5 59.0%; Southern Plains 5 64.1%;
Pacific Coast 5 55.6%; Southwest 5 87.5%. Details of
the IHS regions (Alaska, Pacific Coast, Northern
Plains, Southern Plains, Southwest, and East) and
CHSDA areas are provided elsewhere26 and shown
in Figure 1.
Population Estimates
County-level population estimates produced by the
US Census Bureau were used as denominators in the
rate calculations. To manage multiple race data col-
lected since 2000, a technique of bridging race cate-
gories into single-race annual population estimates
was developed by the CDC’s National Center for
Health Statistics in collaboration with the Census Bu-
reau.35 The NCI makes further refinements regarding
race and county geographic codes and provides pub-
lic access to these estimates at the SEER Website.36
Statistical Analyses
Two sets of statistics are provided for AI/AN and
NHW populations: 1) data from all counties in all
states that meet cancer registry data quality criteria
(referred to as ‘‘All Counties’’), and 2) data from
CHSDA counties in all states that meet quality crite-
ria. In addition, All-Counties data and CHSDA coun-
ties data are provided for each IHS region. The
FIGURE 1. States and Contract Health Service Delivery Area (CHSDA) counties by Indian Health Service region are shown.
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results described in the text refer to persons who re-
side in CHSDA counties, unless otherwise noted.
Additional information about cases and population
coverage is available elsewhere.26
For all AI/AN and NHW populations, cancer inci-
dence rates are expressed per 100,000 persons and are
age-adjusted by 19 age groups (<1, 1-4, 5-9, . . ., 80-84,
85) to the 2000 US standard population by use of the
direct method.28 Percent distributions are also age-
adjusted.37 Rate ratios with 95% confidence intervals
(CI) are provided for regional comparisons of incidence
rates between AI/AN and NHW populations (Table 1).
Rate ratios are calculated as the age-adjusted incidence
among AI/AN persons divided by the age-adjusted inci-
dence among NHW persons. For all analyses, case
counts are suppressed when the category of interest
contains <6 cases. Annual percent change (APC) was
used to describe fixed interval trends from 1999 to
2004. Incidence rates, rate ratios, APC, and 95% modi-
fied gamma CI (95% CI)38 are generated by use of
SEER*Stat Software, Version 6.3.6.39
RESULTS
Cancer Incidence
From 1999 to 2004, there were 681 cases of liver can-
cer diagnosed in AI/AN in all regions (Table 1) and
54,317 cases diagnosed in NHW in all regions. When
the analysis was restricted to CHSDA counties, there
were 529 cases of liver cancer diagnosed in AI/AN
(Table 1) and 11,805 cases diagnosed in NHW. Only
63.7% of the 529 AI/AN cases and 71.2% of the 11,805
NHW cases were microscopically confirmed. Micro-
scopically confirmed cancers among AI/AN cases
were 77.8% hepatocellular carcinoma, 7.1% cholan-
giocarcinoma, 6.2% other malignant histologies, 3.9%
other adenocarcinomas, 3.7% adenocarcinoma not
otherwise specified, and 1.2% combined hepatocellu-
lar and cholangiocarcinoma (Table 2). The microsco-
pically confirmed cases among NHW were 66.7%,
13.4%, 8.2%, 3.3%, 7.5%, and 1.0%, respectively. The
higher proportion of HCC among AI/AN compared
with NHW was consistent when the analysis was
repeated using all cases, with the exception of the
East. Because of the small number of AI/AN cases, the
analyses will include all primary liver cancers, rather
than being restricted to hepatocellular carcinoma.
Of the 681 cases of liver cancer diagnosed among
AI/AN, 77.7% of all incident cases were diagnosed
among AI/AN residents of CHSDA counties (Table 1).
Liver cancer incidence rates for AI/AN populations
residing in CHSDA counties were uniformly higher
than rates based on AI/AN residents in All Counties,
with the exception of Alaska, where all counties are
designated as CHSDA counties. In contrast, there
was very little difference in NHW rates between
CHDSA counties and All Counties. These findings are
TABLE 2
Invasive Liver and Intrahepatic Bile Duct Cancer Percentage Histology Distribution Among Microscopically Confirmed Cases by Indian Health
Service Region for American Indians/Alaska Natives and Non-Hispanic Whites, CHSDA Counties, United States, 1999 to 2004
IHS Region
Adenocarcinoma,
NOSa Cholangiocarcinomab
Combined
Hepatocellular and
Cholangiocarcinomac
Hepatocellular
Carcinomad
Other
Adenocarcinomase
Other Malignant
Histologies
AI/AN, %f NHW, %f AI/AN, %f NHW, %f AI/AN, %f NHW, %f AI/AN, %f NHW, %f AI/AN, %f NHW, %f AI/AN, %f NHW, %f
Northern Plains 1.3 11.5 11.4 16.1 3.4 1.4 73.6 59.9 6.1 2.9 4.3 8.6
Alaska  8.0 6.8 12.2  4.1 70.7 64.5 14.7 1.5 7.7 9.7
Southern Plains 6.4 13.8 3.7 11.1 1.8 0.7 79.8 56.1 2.3 5.2 5.8 13.1
Pacific Coast 2.3 6.3 9.0 13.6 1.5 0.7 81.6 68.1  3.7 5.8 7.3
East  5.8  13.1  1.7 74.5 69.2 12.5 2.3 13.0 7.8
Southwest 6.1 7.2 7.6 11.0  1.0 76.6 70.3 3.3 3.1 6.5 6.9
Total 3.7 7.5 7.1 13.4 1.2 1.0 77.8 66.7 3.9 3.3 6.2 8.2
Source: Cancer registries in the National Program of Cancer Registries of the Centers for Disease Control and Prevention and the Surveillance, Epidemiology, and End Results program of the National Cancer
Institute; see Table 1 for states included.
CHSDA indicates Contract Health Service Delivery Areas; NOS, not otherwise specified; IHS, Indian Health Service; AI/AN: American Indians/Alaska Natives; NHW: non-Hispanic whites.
a Includes histology 8140.
b Includes histology 8160.
c Includes histology 8180.
d Includes histologies 8170 to 8175.
e Includes histologies 8141 to 8159, 8161 to 8169, 8176 to 8179, 8181 to 8389, 8401, 8408, 8410, 8411, 8413, 8441, 8450, 8460, 8470, 8480 to 8482, 8490, 8500, 8503, 8504, 8510, 8520, 8525, 8530, 8571 to 8574,
8576, 8650, 9070, 9110.
f Percentages in the histology distribution are age-adjusted to the 2000 US standard population and may not add to 100.0% due to rounding.
 If no cases were reported, then percentage distributions could not be calculated.
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consistent with improved classification of AI/AN can-
cer cases within CHSDA counties; the improvement
resulted in increased rates for AI/AN, but it had
minimal effect on NHW rates.
Age-adjusted liver cancer incidence rates (ex-
pressed per 100,000) for AI/AN and NHW persons,
stratified by region, sex, and CHSDA county, are
shown in Table 1. Liver cancer incidence rates
among AI/AN males were statistically significantly
higher than those among NHW males for all regions
except for the East. Rates ranged from 7.3 (95% CI,
3.8-12.6) in the East to 17.2 (95% CI, 10.4-26.3) in
Alaska. In contrast, there was relatively little regional
variation in rates for NHW males, which ranged from
5.4 in the Northern Plains to 8.2 in Alaska.
Like the rates for males, rates per 100,000 among
AI/AN females were statistically significantly higher
than those among NHW females for all regions,
except for the East. Rates per 100,000 ranged from
3.8 (95% CI, 1.4-8.2) in the East to 6.9 (95% CI, 3.6-
11.6) in Alaska. In contrast, there was relatively little
regional variation in rates for NHW females, which
ranged from 2.2 in the Northern Plains to 2.8 in the
Southern Plains.
Age-adjusted liver cancer incidence rates strati-
fied by region and age are shown in Table 3. The AI/
AN rates for all regions were consistently higher than
the NHW rates at every age. The rates in the 45 to
59, 60 to 74, and 751 age groups were statistically
significantly higher than the NHW rates in the North-
ern Plains, Southern Plains, Pacific Coast, Southwest,
and All Regions. In Alaska, only the rates in the 751
age group were statistically significantly higher than
the NHW rates. Differences between AI/AN and
NHW were not statistically significant in the East and
among the <75 age groups in Alaska.
Cancer Stage
Age-adjusted liver cancer incidence rates in CHSDA
counties, stratified by region and stage, are shown in
Table 4. Age-adjusted percent distributions show
AI/AN persons were less likely than NHW to be diag-
nosed with localized (24.7% vs 28.6%) or distant
(13.5% vs 16.7%) liver cancer. AI/AN were more likely
than NHW to be diagnosed with regional or unstaged
cancer. Exceptions were found in the Alaska and Pa-
cific Coast regions, where over 30% of AI/AN were
diagnosed in the localized stage. These 2 regions also
TABLE 3
Invasive Liver and Intrahepatic Bile Duct Cancer Incidence Rates and Percentage Distribution by Age and Indian Health Service Region for
American Indians/Alaska Natives and Non-Hispanic Whites, CHSDA Counties, United States, 1999 to 2004
<45 Years 45-59 Years 60-74 Years 751 Years
IHS Region Count
% of
Casesa Rateb 95% CI Count
% of
Casesa Rateb 95% CI Count
% of
Casesa Rateb 95% CI Count
% of
Casesa Rateb 95% CI
American Indian/Alaska Native
Northern Plains 7 8.9 0.7 0.3-1.4 30 38.0 15.6c 10.5-22.3 25 31.6 33.7c 21.6-50.0 17 21.5 66.6c 38.7-106.9
Alaska  10.0 0.9 0.2-2.3 12 30.0 12.8 6.6-22.4 12 30.0 28.4 14.6-49.9 12 30.0 84.8c 43.6-149.1
Southern Plains  4.8 0.5 0.1-1.0 32 30.5 10.7c 7.3-15.1 41 39.0 29.2c 20.9-39.7 27 25.7 45.4c 29.9-66.2
Pacific Coast 9 7.1 0.6 0.3-1.2 59 46.8 16.3c 12.4-21.0 36 28.6 27.2c 18.9-37.8 22 17.5 48.4c 30.3-73.5
East  10.0 0.6 0.1-2.2 10 50.0 12.0 5.8-22.1  15.0 7.7 1.6-23.7  25.0 38.3 12.4-89.3
Southwest 16 10.1 0.8 0.4-1.2 50 31.4 12.0c 8.9-15.8 52 32.7 27.2c 20.2-35.7 41 25.8 56.8c 40.8-77.1
Total 43 8.1 0.7 0.5-0.9 193 36.5 13.4c 11.5-15.4 169 31.9 27.4c 23.4-31.9 124 23.4 54.1c 45.0-64.5
Non-Hispanic white
Northern Plains 96 5.1 0.3 0.3-0.4 429 22.9 4.6 4.2-5.1 680 36.2 12.9 12.0-13.9 672 35.8 20.4 18.9-22.0
Alaska 14 12.0 0.8 0.4-1.3 52 44.4 8.6 6.4-11.2 35 29.9 18.3 12.6-25.6 16 13.7 24.3 13.8-39.7
Southern Plains 36 4.2 0.4 0.3-0.5 193 22.6 5.6 4.8-6.4 303 35.4 13.9 12.4-15.5 323 37.8 26.1 23.3-29.1
Pacific Coast 213 5.1 0.4 0.4-0.5 1312 31.2 7.4 7.0-7.8 1339 31.8 14.2 13.5-15.0 1346 32.0 22.2 21.0-23.4
East 133 4.5 0.4 0.3-0.5 666 22.5 5.9 5.4-6.4 1082 36.6 15.9 15.0-16.9 1077 36.4 23.4 22.0-24.8
Southwest 91 5.1 0.4 0.4-0.5 490 27.4 6.6 6.1-7.2 691 38.6 14.2 13.2-15.3 516 28.9 19.7 18.1-21.5
Total 583 4.9 0.4 0.4-0.4 3142 26.6 6.3 6.1-6.5 4130 35.0 14.4 14.0-14.8 3950 33.5 22.1 21.4-22.8
Source: Cancer registries in the National Program of Cancer Registries of the Centers for Disease Control and Prevention and the Surveillance, Epidemiology, and End Results program of the National Cancer
Institute; see Table 1 for states included.
CHSDA indicates Contract Health Service Delivery Areas; IHS, Indian Health Service; CI, confidence interval.
a Percentages may not add to 100.0% due to rounding.
b Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups, Census P25-1130).
c AI/AN rate is statistically significantly higher than the NHW rate (P < .05).
 Counts less than 6 are suppressed; if no cases were reported, then row percentages and rates could not be calculated.
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were less likely to have unstaged liver cancer. A large
percentage of cases diagnosed in CHSDA counties
were unstaged for both AI/AN and NHW (38.2% and
33.3%, respectively).
Trends
Finally, because recent studies showed increases in
liver cancer incidence rates and differences in
sex,16,40 incidence rates were examined for AI/AN
and NHW males and females to assess possible
trends (Fig. 2, Table 5). Consistent with published
reports, rates of liver cancer varied by sex (Fig. 2).
Rates of liver cancer among NHW males significantly
increased by 3.8% per year in all regions, whereas
the rates among NHW females decreased slightly by
20.6% per year (Table 5). In contrast, trends for the
smaller AI/AN populations varied considerably by
region. The incidence rates among AI/AN males
increased by 1.4% for all regions and varied from
25.9% in the Southwest to 31.0% in Alaska; however,
none of these changes achieved statistical signifi-
cance. The rates among AI/AN females showed an
increase of 8.2% for all regions and varied from
22.8% in the Pacific Coast to 23.8% in the Northern
Plains; however, the trend among AI/AN females in
the Southern Plains (12.2%) did achieve statistical
significance. There was very little difference in the
FIGURE 2. Liver cancer incidence rates for American Indians/Alaska Natives (AI/AN) and non-Hispanic whites NHW. Source: Cancer registries in National Pro-
gram of Cancer Registries of the Centers for Disease Control and Prevention and/or the Surveillance, Epidemiology, and End Results Program of the National
Cancer Institute. See Table 1 for states included. Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population (19 age groups,
Census P25-1130).
TABLE 5
Invasive Liver and Intrahepatic Bile Duct Cancer Incidence Annual Percentage Change by Year and Indian
Health Service Region for American Indians/Alaska Natives and Non-Hispanic Whites, CHSDA Counties,
United States, 1999 to 2004
Both Sexes Male Female
IHS Region AI/AN APCa NHW APCa AI/AN APCa NHW APCa AI/AN APCa NHW APCa
Northern Plains 8.9 1.3 2.5 2.6 23.8 22.2
Alaska 15.2 23.6 31.0 26.7  20.2
Southern Plains 7.4 0.8 3.0 1.7 12.2b 21.1
Pacific Coast 22.1 4.1b 22.8 5.0b 22.8 1.4
East 7.9 2.4  4.0  22.0
Southwest 0.4 2.9 25.9 3.7 7.3 20.1
Total 4.0 2.6b 1.4 3.8b 8.2 20.6
Source: Cancer registries in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention and the Surveillance, Epidemi-
ology, and End Results program of the National Cancer Institute; see Table 1 for states included.
CHSDA indicates Contract Health Service Delivery Areas; IHS, Indian Health Service; AI/AN, American Indians/Alaska Natives; APC, annual percentage change;
NHW, non-Hispanic whites.
a Percentage changes were calculated using 2 years for each end point; APCs were calculated by using the weighted least-squares method.
b APC is significantly different from zero (P < .05).
 Statistic could not be calculated.
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rates when the analysis was repeated by excluding 5
states that did not have all 6 years of data.
DISCUSSION
By using data from population-based central cancer
registries linked with IHS patient registration records
and restricting data analysis to CHSDA counties, we
found that AI/AN have a higher incidence of primary
liver cancer than previously reported.28,41 Our finding
of higher rates is likely attributable to prior racial mis-
classification of AI/AN as other races, the net result of
which is an underestimation of actual disease risk.17
We also found that both AI/AN and NHW males
experienced higher incidence rates of primary liver
cancer than AI/AN and NHW females, respectively.
Primary liver cancer incidence has been increas-
ing in the general population at the rate of 3.5% per
year in males and 1.6% per year in females from
1995 through 2004.16 Individuals with cirrhosis and
chronic liver disease are at higher risk of liver cancer,
and the main preventable causes of these conditions
are chronic infection with hepatitis B and C viruses,
chronic alcohol abuse, and nonalcoholic fatty liver
disease.16,42
The development of cirrhosis is a necessary pre-
cursor for HCC associated with hepatitis C. Chronic
hepatitis C infection confers an approximately 20%
increased risk of cirrhosis.43-47 Incidence rates based
on reported cases in 2001 indicate that the AI/AN
hepatitis C rate is more than 6 times greater than the
hepatitis C rate in NHW.48 The risk of developing
HCC among cirrhotic hepatitis C patients is approxi-
mately 1% to 4% per year worldwide.45 With an esti-
mated 4.1 million Americans (1.6%) infected with
hepatitis C,43 rates of liver cancer and other compli-
cations of hepatitis C are expected to climb over the
next 20 years.49,50
Elevated liver cancer rates are part of a large
overall disparity in the impact of chronic liver dis-
ease (CLD) on AI/AN populations.18 A nationwide
population-based study found that mortality rates
from CLD/cirrhosis were twice as high among urban
AI/AN than for the general population.51 The age-
specific CLD death rate in AI/AN was over twice as
high as in US whites and blacks, and over 3 times as
high as in Asian/Pacific Islanders.18 Although rates
observed in other racial groups decreased, the age-
adjusted death rates from CLD increased among AI/
AN from 1990 to 1998.18 Several reasons have been
proposed to explain the disparity in AI/AN liver can-
cer rates compared with other populations.
Cirrhosis in itself, regardless of the cause, is a
risk factor for primary liver cancer, and the most
common cause of cirrhosis in the US is alcoholic
liver disease.52 Alcohol-related morbidity varies
across AI/AN communities, but it remains a signifi-
cant health concern for many tribal groups.53 Alcohol
abuse and hepatitis B and C synergistically increase
liver cancer risk6,7 and are likely contributors to dis-
parities between AI/AN and NHW.
A recent IHS/CDC study found that more than
half of prevalent cases of CLD had alcohol-related
liver disease or hepatitis C, or both.54 Self-reported
use of alcohol has been collected by the Behavioral
Risk Factor Surveillance Survey (BRFSS) since 1984.55
The most recent BRFSS data show prevalence rates
of heavy drinking (defined as more than 2 drinks per
day within the past 30 days for males and more than
1 drink per day within the past 30 days for females)
prevalence rates were similar for NHW and AI/AN,
but the data show that binge drinking (defined as
5 or more drinks on 1 occasion within the past 30
days) is more prevalent in AI/AN.56 Although the
rates of heavy drinking are similar in the 2 popula-
tions, interactions between chronic hepatitis infec-
tions and heavy alcohol use may cause higher rates
of cirrhosis, thereby leading to higher rates of HCC
in AI/AN.57,58 The higher rates of primary liver
cancer that we observed in AI/AN males relative to
AI/AN females may be at least partially explained by
higher prevalence in AI/AN males than in AI/AN
females of both hepatitis C-related and alcohol-
related chronic liver disease.54
Other diseases implicated in the development of
cirrhosis and subsequent HCC risk may also dispro-
portionately affect AI/AN populations. Primary bili-
ary cirrhosis (PBC) has been implicated as a cause of
chronic liver disease among Canadian First Nation
peoples in British Columbia.59,60 Among indications
for liver transplant in British Columbia from 1989 to
1998, 25% of persons requiring a transplant for PBC
were of First Nations descent, although persons of
First Nations descent comprise only 4% of the British
Columbia population.60 Thus, there is evidence that
PBC may be more common in AI/AN populations
than in NHW populations, and that PBC may there-
fore contribute to the elevated primary liver cancer
rates we present. A population-based study from
Alaska reported higher rates of autoimmune hepatitis
among Alaska Natives than in a Norwegian popula-
tion,61,62 although the prevalence of autoimmune
hepatitis is unknown in AI/AN in the continental US.
Before the introduction of the hepatitis B vac-
cine, hepatitis B was endemic among AI/AN in
Alaska.63-65 However, routine screening and infant
vaccination programs begun in the early 1980s have
drastically reduced hepatitis B incidence in this
region.63 Unfortunately, little is known about the
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prevalence of chronic viral hepatitis in AI/AN popu-
lations outside of Alaska. Our study illustrates the
need for a better understanding of the relative contri-
butions of hepatitis C, hepatitis B, and alcohol abuse
to elevated liver cancer rates in AI/AN.
Diabetes and obesity prevalence may also be
partially responsible for primary liver cancer dispari-
ties in AI/AN. Diabetes and obesity have both been
identified as emerging risk factors for HCC because
of their being risk factors for NASH.66,67 NASH can
result in cirrhosis, and it is thought to be responsible
for a significant proportion of cryptogenic cirrhosis
and HCC.68,69 AI/AN in all regions have a higher
prevalence of obesity than NHW and AI/AN have an
elevated prevalence of diabetes.56,70,71 It is likely that
NASH plays a significant role in the development of
HCC in AI/AN.
Cigarette smoking has also been implicated as
an etiologic agent in the development of multiple
cancers, including HCC,72 and evidence suggests a
synergistic effect between tobacco use, alcohol con-
sumption, and obesity in HCC’s development.3 AI/
AN populations have the highest smoking rates in
the country.56,70,73 During the most recent BRFSS
reporting period (2000-2006),56 31.1% of AI/AN parti-
cipants reported currently being habitual smokers,
compared with 22.8% of NHW participants. AI/AN in
the Southwest reported lower smoking rates than AI/
AN in other regions (21.1%), whereas rates were
40.2% in the Northern Plains and 40.0% in Alaska.
AI/AN males were more likely to smoke than AI/AN
females except in the Southern Plains, where current
smoking rates were nearly the same. The use of
tobacco for traditional purposes in many AI/AN
communities calls for culturally sensitive and specific
cessation programs.
Several limitations need to be considered when
interpreting the results in this report. Although data
linkages between central cancer registry data and
IHS enrollment data reduced racial misclassification
for AI/AN living in CHSDA counties, our algorithm
does not correct for misclassification of those indivi-
duals who are not members of federally recognized
tribes, who are not eligible for IHS services, or who
have not accessed IHS health services. Many AI/AN
who live primarily in urban non-CHSDA areas are
under represented, and thus the findings are not
necessarily generalizable to all AI/AN in the US or in
individual IHS regions.26 Because of the small num-
ber of AI/AN cases, we were not able to restrict our
analyses to HCC only, which comprised 77.8% of our
microscopically confirmed cases.
In summary, AI/AN in all regions experienced
higher primary liver cancer incidence than NHW.
According to BRFSS data, there is a higher burden of
risk factors associated with primary liver cancer—
including diabetes, obesity, cigarette smoking, and
heavy alcohol use—in AI/AN than in NHW. These
factors may contribute to the higher incidence of
primary liver cancer in AI/AN communities. Further-
more, there are likely complex interactions of etiolo-
gic factors yet to be discovered. Data on several of
the most important risk factors for primary liver can-
cer, such as the prevalence of chronic hepatitis B
and C virus infection among AI/AN populations, are
needed.
The high prevalence of known risk factors for
primary liver cancer among AI/AN populations will
make this group of cancers an important health con-
cern for the foreseeable future. Clinical care of AI/AN
individuals should include vaccination against hepa-
titis B, behavioral risk screening for alcohol abuse
and hepatitis B and C risk factors such as intrave-
nous drug use and sexually transmitted infections, as
well as the development of culturally specific weight
management, diabetes, and nontraditional tobacco
cessation programs. Periodic screening with alpha-
fetoprotein or by alpha-fetoprotein and ultrasound
among patients with a high prevalence of known risk
factors has been recommended to detect HCC
tumors at earlier stages; however, it is unclear
whether this screening improves disease-specific or
all-cause mortality.74 Given the higher incidence of
primary liver cancer in AI/AN communities, more
work is needed to determine the potential impact of
programmatic screening in this population.75
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